Sparo Labs has finally started selling its flagship product, Wing, an FDA-cleared, smartphone- and cloud-connected device for measuring and tracking lung function. The device is available to the general public for $129 from the company’s website, requiring no prescriptions of any kind. Shipments are expected to start at the end of this month.
Wing works in tandem with an easy to use companion app that allows users to detect early declines in lung function and take action to prevent asthma attacks, even before any symptoms were noticed. The system alerts if the user’s lung function has declined from “Green” into the “Yellow Zone”, meaning they should use their quick-relief albuterol inhaler to prevent an oncoming attack.
Thanks to the cloud back-end, Wing supports multiple users and makes the data collected available on a web-based interface from where, again, multiple users and doctors (if needed) could access it.
Beyond asthma, Wing is also helpful for people to proactively manage other respiratory conditions, such as COPD and cystic fibrosis.
Founded by Abby Cohen and Andrew Brimer, Sparo Labs started as a crowdfunding project, and has later managed to raise more than $2.7 million. Last year, the St. Louis-based company went on to demo the product to President Obama at the first-ever White House Demo Day in 2015.
It is estimated that one out of every 12 people in the US suffer from asthma (approximately 25 million people), yet asthma is currently managed reactively as many people struggle to recognize early warning signs of an asthma attack until they are having trouble breathing.